The Cholinergic System in the Pathophysiology and Treatment of Alzheimer's Disease

Harald Hampel; M.-Marsel Mesulam; A. Claudio Cuello; Martin R. Farlow; Ezio Giacobini; George T. Grossberg; Ara S. Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J. Snyder; Zaven S. Khachaturian

Disclosures

Brain. 2018;141(7):1917-1933. 

In This Article

Sidebar

References

  1. Andres-Benito P, Fernandez-Duenas V, Carmona M, Escobar LA, Torrejon-Escribano B, Aso E, et al. Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology. Neuropathol. Appl. Neurobiol. 2017; 43: 373–392.

  2. Beaulieu J-M. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J. Psychiatry Neurosci. 2012; 37: 7–16.

  3. Beaulieu J-M, Sotnikova TD, Yao W-D, Kockeritz L, Woodgett JR, Gainetdinov RR, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 5099–5104.

  4. Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, et al. Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Alzheimers. Res. Ther. 2013; 5: 21.

  5. Collins AL, Aitken TJ, Greenfield VY, Ostlund SB, Wassum KM. Nucleus Accumbens Acetylcholine Receptors Modulate Dopamine and Motivation. Neuropsychopharmacology 2016; 41: 2830–2838.

  6. Ehrenberg AJ, Nguy AK, Theofilas P, Dunlop S, Suemoto CK, Di Lorenzo Alho AT, et al. Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer's disease. Neuropathol. Appl. Neurobiol. 2017; 43: 393–408.

  7. Higley MJ, Soler-Llavina GJ, Sabatini BL. Cholinergic modulation of multivesicular release regulates striatal synaptic potency and integration. Nat. Neurosci. 2009; 12: 1121–1128.

  8. Ikonomovic MD, Nocera R, Mizukami K, Armstrong DM. Age-related loss of the AMPA receptor subunits GluR2/3 in the human nucleus basalis of Meynert. Exp. Neurol. 2000; 166: 363–375.

  9. Kim SH, Kandiah N, Hsu J-L, Suthisisang C, Udommongkol C, Dash A. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. Br. J. Pharmacol. 2017; 174: 4224–4232.

  10. Limon A, Reyes-Ruiz JM, Miledi R. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. U. S. A. 2012; 109: 10071–10076.

  11. McNamara CG, Tejero-Cantero A, Trouche S, Campo-Urriza N, Dupret D. Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence. Nat. Neurosci. 2014; 17: 1658–1660.

  12. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998; 18: 407–430.

  13. Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. Nat. Commun. 2017; 8: 14727.

  14. Osborn LM, Kamphuis W, Wadman WJ, Hol EM. Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease. Prog. Neurobiol. 2016; 144: 121–141.

  15. Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 2004; 7: 583–584.

  16. Riemer C, Borroni E, Levet-Trafit B, Martin JR, Poli S, Porter RHP, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J. Med. Chem. 2003; 46: 1273–1276.

  17. Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in aging and Alzheimer's disease. J. Neurochem. 2007; 103: 1285–1292.

  18. Takata N, Mishima T, Hisatsune C, Nagai T, Ebisui E, Mikoshiba K, et al. Astrocyte calcium signaling transforms cholinergic modulation to cortical plasticity in vivo. J. Neurosci. 2011; 31: 18155–18165.

  19. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 2012; 15: 1227–1235.

  20. Vincent AJ, Gasperini R, Foa L, Small DH. Astrocytes in Alzheimer's disease: emerging roles in calcium dysregulation and synaptic plasticity. J. Alzheimers. Dis. 2010; 22: 699–714.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....